Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2

Web Exclusives — December 7, 2022

The FIDES-01 clinical trial was a phase 2, open-label, single-arm study evaluating the efficacy of derazantinib as a second-line therapy in patients with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 gene fusions, mutations, or amplifications. Derazantinib is a potent kinase inhibitor, and similar drugs in this class have been FDA approved for the treatment of CCAs with FGFR alterations. Disruptions in FGFR2 are relatively common in patients with iCCA, with FGFR2 fusions present in approximately 15% of patients and another 5% having mutations or amplifications in FGFR2.

Patients with advanced iCCA characterized as either FGFR fusions or FGFR mutations or amplifications and ≥1 previous line of chemotherapy were treated with derazantinib 300 mg daily (N = 143). FGFR anomalies were confirmed and characterized via fluorescence in situ hybridization or next-generation sequencing. Primary end points for the FIDES-01 trial were objective response rate (ORR) for FGFR2 fusions as assessed by central radiology review, and progression-free survival (PFS) for FGFR2 mutations or amplifications as assessed either radiographically or by survival status.

Median age for the study population was 59 years, and approximately half of the participants had ≥2 previous lines of therapy. Tumor response and safety data were collected from 103 patients in the FGFR2 fusions cohort. In the FGFR2 mutations or amplifications cohort, safety was assessed in 40 patients, and response in 31 patients.

In all, 98% of the 103 patients with FGFR2 fusions discontinued treatment, as did 78% of the 40 patients in the FGFR2 mutations or amplifications cohort. In the FGFR2 fusion group, ORR was 21.4%, and the disease control rate (DCR) was 75.7% (95% confidence interval [CI], 66.3-83.6). Median PFS was 8.0 months (95% CI, 5.5-8.3), and median overall survival (OS) was 17.2 months (95% CI, 12.5-22.4). Patients with FGFR2 mutations or amplifications had a confirmed ORR of 6.5% (95% CI, 0.8-21.4), and the DCR was 58.1% (95% CI, 39.1-75.5). Median PFS in these patients was 8.3 months (95% CI, 1.9-16.7), and median OS was 15.9 months (95% CI, 8.4-not estimable). The most common adverse events (AEs; any grade) observed were hyperphosphatemia (37%), asthenia/fatigue (34%), nausea (30%), transaminase elevations (29%), dry mouth (27%), and dry eye (23%). The majority of AEs were grade 2 or less.

Preliminary data from this small, genetically defined population support the use of derazantinib as a clinically meaningful and targeted second-line therapy for patients with iCCA whose tumors are characterized by genetic aberrations in FGFR2.

Source: Borad M, Javle M, Shaib WL, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications. Ann Oncol. 2022;33(suppl 7):S567-S568.

Related Items

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial
Web Exclusives
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations
Web Exclusives
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA
Web Exclusives
Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.
Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC
Web Exclusives
The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.
Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers
Web Exclusives
A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.
Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC
Web Exclusives
Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.
Immune-Related Adverse Events in the TOPAZ-1 Study of Durvalumab or Placebo plus GemCis in Advanced BTC
Web Exclusives
Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
CCA Summit Live from ESMO 2022
By Juan W. Valle, MB ChB, MSc, FRCP
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.
Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting
By Richard Kim, MD
Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.
Futibatinib Safe and Effective in Patients with Advanced or Metastatic Intrahepatic Cholangiocarcinoma and FGFR2 Fusions
October 2020, Vol 1, No 2
Two phase 2 studies of futibatinib, a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, analyzed data from the FOENIX-CCA2 clinical trial and were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO).

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: